Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


19 Items
Title  Creator  Group name  Publishing year 
ATR inhibition potentiates FOLFIRINOX cytotoxic effect in models of pancreatic ductal adenocarcinoma by remodelling the tumour microenvironment Bruciamacchie et al. EquipeCG 2024-11-29
Improving the response to oxaliplatin by targeting chemotherapy-induced CLDN1 in resistant metastatic colorectal cancer cells Cherradi et al. EquipeMY 2023-04-11
[Molecular signatures in castration-resistant prostate cancers: An update] Houédé and Pourquier EquipeCG 2022-07-21
Multiplexed-Based Assessment of DNA Damage Response to Chemotherapies Using Cell Imaging Cytometry Vezzio-Vié et al. EquipeCTCS 2022-05-20
PXR Modulates the Prostate Cancer Cell Response to Afatinib by Regulating the Expression of the Monocarboxylate Transporter SLC16A1 Matheux et al. EquipeCG 2021-07-20
Inventaire des lésions de l'ADN et principaux mécanismes de réparation de l'ADN Pourquier EquipeCG 2021-03
Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells Corvaglia et al. EquipeCG 2021-06-28
The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor Creusot et al. EquipeCG 2020-07-08
[Genetic and transcriptional evolution alters cancer cell line drug response] Pourquier and Azzi EquipeCG Jan 2019
Carboxylate-functionalized foldamer inhibitors of HIV-1 integrase and Topoisomerase 1: artificial analogues of DNA mimic proteins Corvaglia et al. EquipeCG May 10, 2019
[How to manipulate DNA repair to generate neoantigens and ameliorate the efficacy of immunotherapies] Pourquier EquipeCG Aug 23, 2018
Single helically folded aromatic oligoamides that mimic the charge surface of double-stranded B-DNA Ziach et al. EquipeCG May 2018
Safety and efficacy of temsirolimus as second line treatment for patients with recurrent bladder cancer Pulido et al. EquipeCG 02 17, 2018
Redox mechanism of levobupivacaine cytostatic effect on human prostate cancer cells Jose et al. EquipeCG 09 2018
Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial Italiano et al. EquipeCG May 2018
LINE-1 as a therapeutic target for castration-resistant prostate cancer Houede et al. EquipeCG Jan 01, 2018
Association of NR1I2, CYP3A5 and ABCB1 genetic polymorphisms with variability of temsirolimus pharmacokinetics and toxicity in patients with metastatic bladder cancer Mbatchi et al. EquipeCG Sep 2017
Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination Mbatchi et al. EquipeCG 2015
From old alkylating agents to new minor groove binders Puyo et al. EquipeCG Jan 2014
19 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés